AstraZeneca : announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions - Form 6-K -November 01, 2023 at 06:42 am EDT

a0076s

FORM 6-K


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Washington ,United States ,Boston ,Massachusetts ,Adrian Kemp ,Marc Dunoyer ,Company Secretary ,Alexion Pharmaceuticals Inc ,Securities Exchange ,Investor Relations Team ,Commission File Number ,Astrazeneca ,Nasdaq ,Foreign Issuer ,Securities Exchange Act ,File Number ,Crick Avenue ,Regulationst Rule ,Chief Strategy Officer ,Chief Executive Officer ,Astrazeneca Rare Disease ,Alexion Pharmaceuticals ,Rare Diseases ,Markets ,